Duel of the inflammatory master regulators—insights for drug discovery

April 11, 2018 by Quinn Eastman, Emory University
Duel of the inflammatory master regulators—insights for drug discovery
Figure: Diagram of the glucocorticoid receptor binding a NF-kappaB site. Credit: Hudson et al, Nature Communications (2018).

Anti-inflammatory drugs such as dexamethasone can have harmful side effects on the skin, bones and metabolism. Structural biology research from Emory University School of Medicine has implications for the long-standing quest to separate these drugs' benefits from their side effects.

The findings were recently published in Nature Communications.

Dexamethasone is a synthetic glucocorticoid hormone, used to treat conditions such as allergies, asthma, autoimmune diseases and cancer. It mimics the action of the natural hormone cortisol. Both cortisol and synthetic hormones act by binding the glucocorticoid receptor (GR) protein.

GR can bind DNA in two modes. At some sites, it pairs up or "dimerizes" – turning genes on. At others, it binds one at a time, turning genes off. For GR-targeting drugs, the side effects are thought to come from turning on genes involved in processes such as metabolism and bone growth, while the desired anti-inflammatory effects result mainly from turning inflammatory and immune system genes off.

In their new paper, Eric Ortlund, Ph.D., and colleagues report that GR's ability to directly bind DNA extends more broadly than previously appreciated. The first author is Will Hudson, Ph.D., previously a graduate student with Ortlund and now a postdoctoral fellow in Rafi Ahmed's lab at Emory Vaccine Center.

GR was known to interfere with another important DNA-binding protein called NFkB, a master regulator of inflammation. Ortlund's team found that GR can directly bind one at a time to many of the same stretches of DNA that NFkB interacts with.

"This type of interaction, where GR is acting one at a time – we think it's druggable," says Ortlund, who is associate professor of biochemistry at Emory University School of Medicine.

He adds that the paper's findings could lead to the reinterpretation of several studies in the field of inflammatory gene regulation. GR was previously proposed to interact with NFkB sites by "tethering," based on protein-protein interactions.

Ortlund notes that mutations that interfere with the ability of GR to dimerize do not affect its ability to turn down inflammation. On the other hand, mutations that disrupt its ability to bind DNA foil both its activating and repressing functions.

The researchers measured the affinity between GR protein and DNA at NFkB-binding sites and showed that it was similar to other hormone-driven interactions GR was well-known for. They also probed the mode of interaction between GR protein and NFkB -binding sites, using both X-ray crystallography and NMR (). They showed that GR binds those sites one at a time, in a region that is actually in between the two stretches of DNA contacted by NFkB itself.

Are the same kinds of interactions happening in cells? Hudson, Ortlund and colleagues re-analyzed data from others to show that direct one-at-a time DNA binding by GR could be responsible for repression of many inflammation .

Explore further: Steroid hormone receptor prefers working alone to shut off immune system genes

More information: William H. Hudson et al. Cryptic glucocorticoid receptor-binding sites pervade genomic NF-κB response elements, Nature Communications (2018). DOI: 10.1038/s41467-018-03780-1

Related Stories

Solving a liver receptor puzzle

December 6, 2016

Imagine a key that opens a pin tumbler lock. A very similar key can also fit into the lock, but upside down in comparison to the first key.

Study: How life generates new forms

April 9, 2018

When organisms change during the course of evolution, often what drives new forms is not genes themselves, but gene regulation —what turns genes on and off. A new study identifies the kind of gene regulation most likely ...

Recommended for you

Seeing small-molecule interactions inside cells

December 12, 2018

Like people in a large company, proteins in cells constantly interact with each other to perform various jobs. To develop new disease therapies, researchers are trying to control these interactions with small-molecule drugs ...

The stiffest porous lightweight materials ever

December 12, 2018

Researchers at ETH have developed and manufactured a family of architectures that maximises the stiffness of porous lightweight materials. It's practically impossible to develop stiffer designs.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.